Gilead Sciences

The U.S. Centers for Disease Control and Prevention (CDC) developed the clinical evidence and holds four core patents underlying PrEP — the HIV prevention regimen built around Truvada (tenofovir disoproxil fumarate/emtricitabine). Hundreds of millions in taxpayer dollars funded the trials. Gilead manufactured Truvada and charged $14,000 per year at launch (2012), raising the price to over $22,000 per year by 2019. The cost to manufacture: approximately $60 per year. In 2018, Truvada generated $3 billion in U.S. revenue alone. The identical drug was available generically in other countries for approximately $8 per month. Representative Alexandria Ocasio-Cortez put the question directly to Gilead's CEO at a May 2019 House Oversight hearing: "Why is it $8 in Australia?" In November 2019, the U.S. Department of Justice filed suit against Gilead for patent infringement on behalf of HHS. The government described Gilead's conduct as "malicious, wanton, deliberate, consciously wrongful, flagrant, and in bad faith" and sought over $1 billion in damages. After a 2023 trial in which a Delaware jury found the CDC patents invalid — a decision the government appealed — the parties settled in January 2025. Gilead accrued approximately $200 million. Gilead received freedom to operate. No HIV patient received a cent. When Truvada generic entry arrived in October 2020, Gilead had already shifted its marketing toward Descovy — a reformulation priced at over $26,000 per year — steering patients away from the now-generic drug and onto a second patent-protected extraction cycle.

• —CDC holds 4 patents on PrEP clinical regimens; hundreds of millions in taxpayer dollars funded the underlying trials.
• —Truvada launch price: $14,000/yr (2012). By 2019: $22,000+/yr. Gilead manufacturing cost: ~$60/yr.
• —$3 billion in 2018 U.S. revenue from a drug that costs ~$60/year to manufacture.
• —Identical drug available in other countries for approximately $8/month.
• —Rep. Alexandria Ocasio-Cortez to Gilead CEO (House Oversight, May 2019): "Why is it $8 in Australia?"
• —Approximately 1.1 million Americans identified by the CDC as at substantial risk for HIV should have been offered PrEP.
• —DOJ suit (November 2019): Gilead's conduct characterized as "malicious, wanton, deliberate, consciously wrongful, flagrant, and in bad faith."
• —Government sought $1B+ ($691M for Truvada, $311M for Descovy). 2023 trial: jury found CDC patents invalid.
• —January 2025 settlement: Gilead accrued ~$200 million. Gilead received "freedom to operate." No patient compensated.
• —Product-hopping to Descovy ($26,000+/yr) as Truvada generics arrived in October 2020 — second patent-protected extraction on the same therapeutic class.

In January 2012, Gilead acquired Pharmasset — a clinical-stage company whose primary asset was sofosbuvir (Sovaldi) — for $11.2 billion, paying an 89% premium over Pharmasset's trading price. Pharmasset's own financial projections had valued the drug at $36,000 per treatment course. Gilead set the U.S. price at $84,000 — more than twice Pharmasset's own estimate. The same treatment cost $900 in Egypt and India. In December 2015, Senators Ron Wyden (D-OR) and Chuck Grassley (R-IA) released the results of an 18-month bipartisan Senate Finance Committee investigation based on 20,000 pages of Gilead's internal documents. Their conclusion: the pricing strategy was "designed to maximize revenue with little concern for access or affordability." Internal documents showed Gilead identified "the value capture opportunity is in Wave 1" — meaning the plan was to extract maximum revenue before competition arrived. Staff were instructed to "not fold to advocacy pressure." Because of the price, state Medicaid programs began rationing the cure — requiring advanced liver disease (Stage F3/F4 cirrhosis) before authorizing treatment. Patients with curable early-stage disease were denied and told to wait. In 2014, Medicaid spent $1.3 billion on Sovaldi before rebates and treated less than 2.4% of enrolled hepatitis C patients. Harvoni, the follow-on drug, was priced at $94,500 per course. Hepatitis C kills approximately 15,000 Americans per year.

• —Pharmasset acquired January 2012 for $11.2 billion — 89% premium over trading price. Pharmasset's own projection: $36,000/course.
• —Gilead's U.S. launch price: $84,000/course — more than twice the acquired company's own projection.
• —Same treatment: $900 in Egypt and India; ~$4.29/pill generic manufacturing cost.
• —18-month bipartisan Senate Finance Committee investigation (Wyden + Grassley, December 2015) based on 20,000 internal Gilead documents.
• —Internal documents: "the value capture opportunity is in Wave 1"; staff instructed to "not fold to advocacy pressure."
• —Senate finding: pricing strategy "designed to maximize revenue with little concern for access or affordability."
• —Internal pricing models showed Gilead considered a $50,000–$115,000 range and weighed "activist and public relations blowback" — not access — against revenue targets.
• —2014 Medicaid: $1.3B spent on Sovaldi before rebates; less than 2.4% of enrolled HCV patients treated.
• —State Medicaid programs rationed access, requiring advanced liver cirrhosis (Stage F3/F4) before authorizing coverage for a curable disease.
• —Harvoni (follow-on drug): $94,500/course. Peak Gilead hepatitis C revenue: over $19 billion in a single year (2015).

Remdesivir — Gilead's antiviral treatment for COVID-19 — was developed with direct National Institutes of Health (NIH) investment of at least $70.5 million. NIH's broader investment in related coronavirus research from 2000 through 2019 totaled approximately $6.5 billion. Representative Lloyd Doggett (D-TX): "Without a taxpayer investment of $99 million, this drug would have been abandoned." In June 2020, as remdesivir became the first FDA-authorized COVID-19 treatment, Gilead set the U.S. price at $3,120 per course for privately insured patients. The Institute for Clinical and Economic Review (ICER) calculated that Gilead could still make a profit charging $310 per course — one-tenth the announced price. The Campaign for Sustainable Rx Pricing estimated profit margins north of 90 percent. (That profit margin figure is the Campaign for Sustainable Rx Pricing's estimate; it is cited as such.) Early drafts of COVID-19 relief legislation had included a provision requiring that drugs and vaccines developed with taxpayer funding be priced affordably. That provision did not survive. Gilead's federal lobbying expenditure in Q1 2020 was the highest on record. The United States was the only developed country where Gilead charged two separate prices — one for government payers, one for private insurers.

• —At least $70.5 million in direct NIH investment in remdesivir; ~$6.5 billion in NIH coronavirus research 2000–2019.
• —Rep. Lloyd Doggett (D-TX): "Without a taxpayer investment of $99 million, this drug would have been abandoned."
• —Gilead June 2020 U.S. price: $3,120/course for privately insured patients.
• —ICER: Gilead could make a profit charging $310/course — one-tenth of the announced price.
• —Campaign for Sustainable Rx Pricing: profit margins north of 90 percent (cited as that organization's estimate).
• —Gilead Q1 2020 federal lobbying spend: highest on record at that time.
• —COVID-19 relief bill provision requiring affordable pricing for taxpayer-funded drugs was stripped from the final legislation.
• —United States was the only developed country where Gilead charged two prices (government vs. private insurer).
• —No criminal charges. No enforcement action. Gilead's stock price rose during the public health emergency.

In 2013 — the same year the FDA approved Sovaldi — Gilead transferred its sofosbuvir intellectual property to an Irish subsidiary (Gilead Biopharma) incorporated in Ireland but declared tax-resident in the Bahamas, which has no corporate income tax. This is the "Double Irish" structure: an entity incorporated in Ireland but resident for tax purposes elsewhere, exploiting a gap between Irish and U.S. tax law. The mechanics: U.S. profits flowed to the Irish operating entity as royalty payments for use of the drug's IP. The Irish operating entity paid royalties to the Irish-registered-but-Bahamas-resident holding company. The holding company paid taxes in neither Ireland nor the United States. The structure was purpose-built for the peak Sovaldi revenue window. By end of 2015, Gilead disclosed in its SEC filings that it had accumulated $28.5 billion in untaxed foreign profits and was able to defer $9.7 billion in U.S. tax payments on those profits. Its effective foreign tax rate: approximately 1%. Americans for Tax Fairness reported that the structure increased Gilead's pre-tax profits fivefold between 2013 and 2015 — from $4.2 billion to $21.7 billion. Ireland closed the Double Irish loophole in its 2015 budget, requiring that companies incorporated in Ireland be tax-resident in Ireland. Gilead's structure had been designed for exactly this window. No U.S. enforcement action followed. No criminal charges were filed.

• —Gilead transferred Sovaldi (sofosbuvir) IP to an Irish subsidiary (Gilead Biopharma) declared tax-resident in the Bahamas in 2013 — the year of FDA approval.
• —"Double Irish" structure: incorporated in Ireland; pays taxes in Bahamas — neither Ireland nor the U.S. collected meaningful tax.
• —Mechanics: U.S. profits flow to Irish operating entity as royalties; Irish entity pays royalties to Bahamas-resident holding company.
• —By end of 2015 (per Gilead SEC disclosures): $28.5 billion in untaxed foreign profits.
• —$9.7 billion in deferred U.S. tax payments on those profits.
• —Effective foreign tax rate: approximately 1%.
• —Americans for Tax Fairness: the structure increased Gilead's pre-tax profits fivefold between 2013 and 2015 — from $4.2 billion to $21.7 billion.
• —Ireland closed the Double Irish loophole in its 2015 budget; the structure was designed for exactly this revenue window.
• —No U.S. enforcement action. No criminal charges.

Tenofovir disoproxil fumarate (TDF) is the active ingredient in Truvada and several other Gilead HIV drugs. Internal Gilead emails from 2003 — first reported by STAT News in 2024 — confirm that Gilead's own scientists already knew that its successor compound, tenofovir alafenamide (TAF), was safer for patients' kidneys and bones than TDF. The company had this knowledge internally for over a decade before TAF reached patients. Despite this knowledge, Gilead suspended TAF development, slow-walked FDA submission milestones, and timed TAF's market entry to coincide approximately with TDF's patent expiration. When TDF went generic in 2020, prescribers and patients faced pressure to switch to TAF — a patent-protected drug Gilead marketed as a significant clinical advance. The advance was real. Gilead had known about it since 2003. Millions of HIV patients took a drug Gilead knew caused more kidney and bone harm — for over a decade — while a safer internal alternative was deliberately withheld to protect market exclusivity. TAF was eventually approved in 2015–2016 and priced above the now-generic TDF. (Note: The STAT News 2024 article documenting the 2003 internal emails is the primary citation for this charge; the specific URL is pending verifier confirmation. The fact pattern is also supported by the TAF development timeline.)

• —Internal Gilead emails from 2003 confirm the company knew TAF was safer for kidneys and bones than TDF (reported by STAT News, 2024).
• —STAT News 2024 reporting based on internal documents; specific article URL is documented in the research ledger and pending verifier live-URL confirmation.
• —Gilead suspended TAF development and slow-walked FDA submission milestones for over 10 years despite knowing TAF was safer.
• —TAF launch timing: coincided approximately with TDF patent expiration (TDF generics arrived 2020; TAF approved 2015–2016).
• —Effect: patients facing generic-TDF switch were steered toward patent-protected TAF — priced above generics.
• —Millions of HIV patients experienced preventable kidney and bone harm during the suppression window.
• —Gilead marketed TAF as a clinical advance on approval — the same advance it had suppressed for over a decade.
• —No criminal charges. No regulatory enforcement for the delay.

On June 18, 2025, the FDA approved lenacapavir (brand: Yeztugo) as the first long-acting PrEP option — a twice-yearly injectable HIV prevention drug with near-100% efficacy in clinical trials. Gilead Sciences priced it at $28,218 per person per year in the United States. An academic analysis presented at the 2025 IDWeek conference in Atlanta found that generic lenacapavir could be manufactured and delivered for $25 per person per year at scale (5–10 million treatments annually). Even at two million treatments per year, the cost was $35–46 per person. Gilead's list price is approximately 1,000 times the cost of generic manufacture. UNAIDS responded: "It is beyond comprehension how Gilead can justify a price of $28,218. Drop the price, expand production, and ensure the world has a shot at ending AIDS." Andrew Hill of Liverpool University noted that "even high-income countries will not be able to afford widescale use of lenacapavir at prices above $20,000 per year." Gilead signed generic licensing agreements covering 120 low- and middle-income countries — but as of mid-2025, no actual per-dose price for those agreements had been disclosed. High-income countries outside the U.S. were left without a viable access path. The drug was different. The math was the same.

• —FDA approved lenacapavir (Yeztugo) on June 18, 2025 — first long-acting, twice-yearly PrEP injection; near-100% HIV prevention efficacy in trials.
• —Gilead U.S. list price: $28,218 per person per year.
• —IDWeek 2025 academic analysis (Atlanta): generic manufacture and delivery cost $25/yr at scale (5–10M treatments); $35–46/yr at 2M.
• —Price-to-manufacture ratio: approximately 1,000 to 1.
• —UNAIDS (June 18, 2025): "It is beyond comprehension how Gilead can justify a price of $28,218. Drop the price, expand production, and ensure the world has a shot at ending AIDS."
• —Andrew Hill (Liverpool University): "even high-income countries will not be able to afford widescale use of lenacapavir at prices above $20,000 per year."
• —Gilead signed generic licensing agreements for 120 low- and middle-income countries; no per-dose price disclosed as of mid-2025.
• —High-income countries outside the U.S.: no viable access pathway established.
• —No criminal charges. No enforcement action.